文献速递血管炎

AYLo研究:巨细胞动脉炎合并Y染色体嵌合缺失患者的复发风险升高及促炎信号失调

AYLo study-elevated relapse risk and dysregulated proinflammatory signalling in giant cell arteritis patients with mosaic loss of the Y chromosome.
PubMed 文献 · Ann Rheum Dis · 2025-07-15

该前瞻性研究纳入74例巨细胞动脉炎(GCA)患者,分析白细胞Y染色体嵌合缺失(mLOY)负荷与疾病活动的关系。mLOY>10.2%是复发的独立预测因素(HR 17.4,95%CI 3.5-86.0,P=.003),且与IL-6等促炎因子水平相关。作者认为mLOY可作为预后生物标志物,并可能参与GCA病理生理过程。

要点

  • 74例GCA患者中复发率为23.0%,mLOY中位负荷为17.8%(SD 23.7%)。
  • mLOY>10.2%者复发风险显著更高(P<.001),无复发生存期更短(647 vs 992天)。
  • mLOY>10.2%是复发的独立预测因素(HR 17.4,95%CI 3.5-86.0,P=.003)。

核心结论

  • 本研究首次识别mLOY为GCA复发风险的强独立预测因素,并将mLOY与GCA中促炎信号调控联系起来。
  • 作者认为mLOY可作为预后生物标志物,并强调其可能在GCA病理生理中发挥作用。

研究设计与样本

  • 前瞻性纳入确诊GCA患者,分析其白细胞mLOY负荷。
  • 采用受试者工作特征曲线和约登指数确定预测复发的最佳mLOY阈值。
  • 采用Kaplan-Meier分析和log-rank检验评估无复发生存期,采用多重阵列定量选定促炎细胞因子水平。
  • 共纳入74例GCA患者(平均76.0岁;SD 10.7)。

主要发现

  • 入组时25.7%(19/74)的患者存在活动性疾病,23.0%的患者发生复发。
  • mLOY负荷中位数为17.8%(SD 23.7%),预测复发的最佳阈值为10.2%。
  • 超过该阈值的患者复发风险显著更高(P<.001),无复发生存期更短(647 vs 992天;P<.001)。
  • 多变量Cox回归证实mLOY>10.2%是复发的独立预测因素(HR 17.4;95%CI 3.5-86.0;P=.003)。
  • 多重分析中,全队列mLOY与白介素(IL)-6正相关(P=.045;r=0.24),缓解期mLOY>10.2%的患者IL-6水平升高(P=.010)。

关键数值与推荐

  • 预测复发的最佳mLOY阈值为10.2%。
  • mLOY>10.2%预测复发的HR为17.4(95%CI 3.5-86.0;P=.003)。
  • mLOY>10.2%者无复发生存期为647天,未超过者(≤10.2%)为992天(P<.001)。

临床怎么用

  • 原文结论未据此给出具体临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To assess the prevalence of mosaic loss of the Y chromosome (mLOY) in giant cell arteritis (GCA) and its impact on disease activity. METHODS: Patients diagnosed with GCA were prospectively recruited, and their leukocyte mLOY burden was analysed. The optimal mLOY threshold for predicting relapse was determined using the receiver operating characteristic curve and Youden index. Relapse-free survival was assessed using Kaplan-Meier analysis with the log-rank test. Levels of selected proinflammatory cytokines were quantified using a multiplex array. RESULTS: A total of 74 GCA patients were enrolled (mean, 76.0 years; SD, 10.7). At inclusion, 25.7% (19/74) of patients exhibited active disease. Relapses occurred in 23.0% of patients. The median mLOY burden was 17.8% (SD, 23.7%). An optimal threshold of 10.2% was identified for predicting relapse. Patients exceeding this cutoff had a significantly higher relapse risk (P < .001) with a shorter relapse-free survival (647 vs 992 days; P < .001). Multivariable Cox regression confirmed mLOY >10.2% as an independent predictor of relapse (hazard ratio, 17.4; 95% CI, 3.5-86.0; P = .003). In multiplex analysis, mLOY was positively associated with interleukin (IL)-6 (P = .045; r = 0.24) across the cohort, with elevated IL-6 levels in remission patients with mLOY >10.2% (P = .010). In patients undergoing IL-6 receptor inhibitor treatment and in remission, mLOY was significantly positively associated with IL-6 (P = .002; r = 0.54) and IL-17A (P = .026; r = 0.40). CONCLUSIONS: This study is the first to identify mLOY as a strong, independent predictor of relapse risk and to link mLOY with modulated proinflammatory signalling in GCA. Our findings suggest mLOY as a prognostic biomarker and underscore its possible role in the pathophysiology of GCA.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Petzinna SM, Kirch SM, Adamson MS, et al. AYLo study-elevated relapse risk and dysregulated proinflammatory signalling in giant cell arteritis patients with mosaic loss of the Y chromosome. Ann Rheum Dis. 2025. PMID: 40664552. doi:10.1016/j.ard.2025.06.2133

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。